BridgeBio Oncology Therapeutics (BBOT) News
NASDAQ: BBOTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
1.81-0.05 (-2.69%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BBOT news summary
We found 2 recent headlines mentioning BridgeBio Oncology Therapeutics (BBOT): 0 in the past week and 1 in the past 30 days, most often from GlobeNewswire. For price context, BBOT is down 2.69% at $1.81. The most recent story, "BBOT Reports Third Quarter 2026 Financial Results and Update on Corporate Progress", was published by GlobeNewswire on Nov 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest BridgeBio Oncology Therapeutics headlines
- BBOT Reports Third Quarter 2026 Financial Results and Update on Corporate ProgressSOUTH SAN FRANCISCO, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway…GlobeNewswire
- BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway…GlobeNewswire